SCHEMBL16410682

SCHEMBL16410682

CCC1(CC)Nc2ccc(C(=O)NN)cc2N=C1NNCc1cccc(Cl)c1

nearest known ligand 0.39

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ HDAC1 Q13547 3/20 0.39
▸ MAPK3 P27361 1/20 0.37
▸ MAPK1 P28482 1/20 0.37
▸ HDAC3 O15379 1/20 0.37
▸ HDAC2 Q92769 1/20 0.37
▸ HDAC6 Q9UBN7 1/20 0.37
▸ ROCK2 O75116 2/20 0.36
▸ ROCK1 Q13464 1/20 0.36
▸ NPC1 O15118 1/20 0.35
▸ CNR1 P21554 5/20 0.35
▸ PDGFRB P09619 1/20 0.35
▸ KDR P35968 1/20 0.35
▸ P2RX7 Q99572 1/20 0.35
▸ CNR2 P34972 1/20 0.34
▸ DRD2 P14416 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16410563 0.78 TP53 (0.38) HDAC1MAPK3MAPK1HDAC3HDAC2
SCHEMBL16410801 0.77 P2RX7 (0.31) P2RX7
SCHEMBL17757611 0.70 PTK2 (0.40) HDAC1MAPK3MAPK1HDAC3HDAC2
SCHEMBL17757582 0.70 PTK2 (0.40) HDAC1MAPK3MAPK1HDAC3HDAC2
SCHEMBL17757781 0.70 ACAT2 (0.40) HDAC1MAPK3MAPK1HDAC3HDAC2
SCHEMBL17757065 0.69 DYRK1B (0.39) HDAC1MAPK3MAPK1HDAC3HDAC2
SCHEMBL16410671 0.69 HDAC1 (0.33) HDAC1HDAC3HDAC2HDAC6ROCK2
SCHEMBL16410725 0.68 KDM4E (0.40) ROCK1NPC1
SCHEMBL17757612 0.68 VNN1 (0.43) HDAC1MAPK3MAPK1HDAC3HDAC2
SCHEMBL17757571 0.67 VNN1 (0.43) HDAC1MAPK3MAPK1HDAC3HDAC2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2015007730-A1 SPIROQUINOXALINE DERIVATIVES AS INHIBITORS OF NON-APOPTOTIC REGULATED CELL-DEATH Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) (DE) 2015-01-22 — — WO disclosed
Send feedback